Eagle Pharmaceuticals, Inc. v. Baxter Healthcare Corporation
1:25-cv-00079
Overview
Parties
Defendant
Baxter Healthcare Corporation NPE (Individual / Inventor)
Represented By
0 Attorneys ListedPlaintiff
Eagle Pharmaceuticals, Inc. Operating Company
Represented By
3 Attorneys ListedMcCarter & English, LLP
405 N. King Street, Wilmington, DE 19801
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 13 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US12138248
Formulations of bendamustine
|
Filed: 2024-04-25
Issued: 2024-11-12
|
Active (17.4 yrs remaining)
Expires: 2044-04-25
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked.
Procedural Motions & Interlocutory Orders
Total Motions
5
Dispositive
0
Granted
0
Denied
0
Pending / Review
3
Motions by Category
Key Dispositive Motions & Rulings